NASDAQ:RXST RxSight Q3 2026 Earnings Date & Estimates $4.81 -0.04 (-0.82%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.77 -0.04 (-0.91%) As of 10/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. RxSight is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from RxSight in Q3 2026RxSight is expected to post earnings of -$0.29 per share on revenue of $27.19 million. In the same quarter a year earlier RxSight reported -$0.04 per share on revenue of $30.34 million. RxSight last reported on August 5, 2026, posting -$0.29 per share and beating the -$0.3294 consensus estimate. RxSight has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.29Expected Revenue$27.19 millionPrior-Year EPS-$0.04Prior-Year Revenue$30.34 millionExpected Revenue Growth-10.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.29 (Beat by +$0.0394)Last Quarter Revenue$33.74 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ3 2025 Earnings ReportQ2 2025 Earnings Report RxSight Q3 2026 Earnings FAQ When does RxSight report Q3 2026 earnings? RxSight (NASDAQ:RXST) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. What time is RxSight's Q3 2026 earnings call? RxSight's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for RxSight? Analysts expect RxSight to post earnings of -$0.29 per share for Q3 2026. How much revenue is RxSight expected to report? The consensus revenue estimate for RxSight is $27.19 million for Q3 2026. RxSight Earnings HeadlinesAnalyzing Organigram Global (NASDAQ:OGI) & RxSight (NASDAQ:RXST)October 8 at 5:44 AM | americanbankingnews.comRxSight, Inc. (RXST) Interactive Stock Chart - Yahoo FinanceOctober 7, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Envoy Medical (NASDAQ:COCH) versus RxSight (NASDAQ:RXST) Head to Head ReviewOctober 6, 2026 | americanbankingnews.comCritical Comparison: RxSight (NASDAQ:RXST) and Jushi (OTCMKTS:JUSHF)October 6, 2026 | americanbankingnews.comComparing RxSight (NASDAQ:RXST) & GN Store Nord (OTCMKTS:GNNDY)October 5, 2026 | americanbankingnews.comSee More RxSight Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email. Email Address About RxSightRxSight (NASDAQ:RXST) is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to adjust a patient’s vision after surgery rather than relying solely on preoperative measurements and the initial implanted lens. Its primary products include the RxSight Light Adjustable Lens and the RxSight Light Delivery Device. The lens is implanted during cataract surgery and can be adjusted after surgery through controlled ultraviolet-light treatments delivered by the company’s device. These treatments are intended to help ophthalmologists customize the lens power and optimize a patient’s postoperative vision. RxSight’s technology is marketed to ophthalmic surgeons, eye-care providers and ambulatory surgery centers. The company is based in Aliso Viejo, California, and serves the United States as well as select international markets through its commercial operations and distribution relationships. Its business is centered on the cataract-surgery market and the adoption of light-adjustable intraocular lens technology.View RxSight ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
